Press launch information from Globe Newswire. The AP information employees was not included in its creation.
SAN DIEGO, Jan. 21, 2021 (Globe NEWSWIRE) — Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical firm centered on establishing novel, transformative medicines for neurological diseases, nowadays announced the appointment of Brandi L. Roberts as its Chief Monetary Officer.
“Brandi’s powerful monetary acumen and expertise within the life sciences sector will be vital as we posture the firm for long-time period advancement and advance our property in a array of neurological illnesses,” said Kevin R. Lind, Longboard’s President and Main Govt Officer. “I am delighted to welcome Brandi to the crew.”
Previously, Ms. Roberts served as Main Monetary Officer of Lineage Cell Therapeutics, Inc. (LCTX) from January 2019 to January 2021. Prior to signing up for Lineage in January 2019, she served as Chief Monetary Officer of REVA Medical, Inc. considering the fact that August 2017. Ms. Roberts beforehand served as Main Financial Officer of Mast Therapeutics, Inc. from January 2013 to April 2017, and as its Senior Vice President, Finance, from March 2011 to January 2013. Earlier, she held senior positions at Alphatec Spine, Inc., Artes Health-related, Inc., Stratagene Corporation, and Pfizer, Inc. Ms. Roberts at present serves as Chair of the Southern California Chapter of the Affiliation of Bioscience Monetary Officers and has served on the Board of Temple Therapeutics BV considering the fact that November 2019. Ms. Roberts provides more than 25 years of general public accounting and finance working experience, which include 22 several years at publicly traded pharmaceutical, medical engineering, and daily life science firms to her placement. Ms. Roberts is a accredited community accountant with the Point out of California and obtained her B.S. diploma in business administration from the College of Arizona and her M.B.A. from the University of San Diego.
About Longboard Prescribed drugs
Longboard Prescribed drugs, Inc. (Longboard) is a clinical-stage biopharmaceutical business focused on developing novel, transformative medicines for neurological diseases. Longboard was fashioned in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to progress a portfolio of centrally performing product candidates created to be remarkably selective for particular G protein-coupled receptors (GPCRs). Longboard’s small molecule solution candidates were being found out of the same system at Arena that signifies a end result of much more than 20 decades of GPCR exploration. Longboard is assessing LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in progress for the potential treatment method of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, entire cannabinoid type 2 receptor agonist, in advancement for the prospective treatment method of neurodegenerative illnesses connected with neuroinflammation triggered by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in progress for the probable treatment of central anxious system neuroinflammatory diseases.